Total Payments
$9,587
2024 Payments
$62.19
Companies
51
Transactions
662
Medicare Patients
5,905
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$9,532 (99.4%)
Education$37.90 (0.4%)
Research$16.82 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,532 | 659 | 99.4% |
| Education | $37.90 | 2 | 0.4% |
| Unspecified | $16.82 | 1 | 0.2% |
Payments by Type
General
$9,570
661 transactions
Research
$16.82
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $2,224 | 176 | $0 (2023) |
| Janssen Biotech, Inc. | $1,693 | 80 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,296 | 103 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,097 | 79 | $0 (2023) |
| PFIZER INC. | $392.82 | 28 | $0 (2023) |
| Gilead Sciences, Inc. | $309.57 | 22 | $0 (2023) |
| Merck Sharp & Dohme LLC | $221.64 | 15 | $0 (2023) |
| UCB, Inc. | $178.12 | 14 | $0 (2020) |
| Shire North American Group Inc | $171.98 | 12 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $148.64 | 12 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.19 | 4 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($34.65) |
| 2023 | $1,793 | 105 | AbbVie Inc. ($482.22) |
| 2022 | $1,537 | 111 | ABBVIE INC. ($350.69) |
| 2021 | $1,343 | 103 | AbbVie Inc. ($371.65) |
| 2020 | $423.91 | 28 | Janssen Biotech, Inc. ($111.39) |
| 2019 | $1,392 | 106 | AbbVie, Inc. ($338.61) |
| 2018 | $1,612 | 109 | Janssen Biotech, Inc. ($431.36) |
| 2017 | $1,422 | 96 | Janssen Biotech, Inc. ($422.98) |
All Payment Transactions
662 individual payment records from CMS Open Payments — Page 2 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/22/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Immunology | ||||||
| 09/20/2023 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Rare Disease | ||||||
| 09/19/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: IMMUNOLOGY | ||||||
| 09/14/2023 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: WATCHMAN_IC | ||||||
| 09/07/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Gastroenterology | ||||||
| 08/31/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | CYLTEZO (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: CNS | ||||||
| 08/30/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/25/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $15.71 | General |
| Category: THERAPY FOR CSID | ||||||
| 08/24/2023 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Oncology | ||||||
| 08/23/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: VIROLOGY | ||||||
| 08/23/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/11/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/02/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Immunology | ||||||
| 08/02/2023 | AbbVie Inc. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2023 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/14/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: IMMUNOLOGY | ||||||
| 07/13/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: Gastroenterology | ||||||
| 07/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.16 | General |
| Category: Neuroscience | ||||||
| 07/12/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/12/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Gastroenterology | ||||||
| 07/06/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/05/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Gastroenterology | ||||||
| 07/03/2023 | Evoke Pharma, Inc. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,533 | 9,149 | $1.1M | $279,039 |
| 2022 | 20 | 1,491 | 9,508 | $805,013 | $287,149 |
| 2021 | 23 | 1,469 | 11,917 | $858,944 | $325,576 |
| 2020 | 23 | 1,412 | 11,863 | $889,494 | $329,003 |
Total Patients
5,905
Total Services
42,437
Medicare Billing
$1.2M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 12 | 7,200 | $561,600 | $124,937 | 22.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 177 | 178 | $113,564 | $33,853 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 195 | 266 | $68,096 | $21,711 | 31.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 184 | 184 | $92,736 | $17,568 | 18.9% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 165 | 185 | $56,795 | $12,943 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 173 | 217 | $37,541 | $12,723 | 33.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 88 | 93 | $32,178 | $6,916 | 21.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 36 | 36 | $16,668 | $6,031 | 36.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 65 | 81 | $14,418 | $4,579 | 31.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 44 | $14,696 | $4,160 | 28.3% |
| 43450 | Dilation of esophagus | Facility | 2023 | 120 | 142 | $27,974 | $3,998 | 14.3% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 27 | 86 | $10,320 | $3,798 | 36.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 26 | 26 | $12,038 | $3,175 | 26.4% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 22 | 91 | $8,281 | $3,098 | 37.4% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 49 | 49 | $12,103 | $3,004 | 24.8% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 14 | 28 | $7,028 | $2,352 | 33.5% |
| 99489 | Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 14 | 41 | $5,412 | $2,003 | 37.0% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 12 | 18 | $7,488 | $1,995 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 21 | $5,334 | $1,865 | 35.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 19 | $3,458 | $1,791 | 51.8% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 14 | 48 | $4,464 | $1,720 | 38.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,860 | $1,707 | 21.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 34 | $5,610 | $1,573 | 28.0% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 11 | 30 | $2,310 | $878.91 | 38.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,072 | $659.36 | 21.5% |
About Dr. David Dresner, M.D
Dr. David Dresner, M.D is a Gastroenterology healthcare provider based in New Albany, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417955667.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Dresner, M.D has received a total of $9,587 in payments from pharmaceutical and medical device companies, with $62.19 received in 2024. These payments were reported across 662 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($9,532).
As a Medicare-enrolled provider, Dresner has provided services to 5,905 Medicare beneficiaries, totaling 42,437 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New Albany, IN
- Active Since 07/12/2005
- Last Updated 05/08/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1417955667
Products in Payments
- STELARA (Biological) $1,451
- XIFAXAN (Drug) $713.85
- Humira (Biological) $585.81
- ENTYVIO (Biological) $355.96
- GATTEX (Drug) $346.39
- TRULANCE (Drug) $297.03
- RINVOQ (Biological) $291.02
- DUPIXENT (Biological) $282.11
- XELJANZ (Drug) $281.88
- Entyvio (Biological) $261.85
- REMICADE (Biological) $242.47
- HUMIRA (Biological) $238.86
- LINZESS (Drug) $238.37
- MAVYRET (Drug) $235.03
- RELISTOR (Drug) $233.75
- Mavyret (Drug) $179.70
- Cimzia (Drug) $178.12
- SKYRIZI (Biological) $166.63
- DIFICID (Drug) $146.80
- Creon (Drug) $145.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New Albany
Jonathan Obert, Md, MD
Gastroenterology — Payments: $138,069
Gastroenterology $138,069
Robert Luckett, M.d, M.D
Gastroenterology — Payments: $23,327
Gastroenterology $23,327
Matthew Mccollough, M.d, M.D
Gastroenterology — Payments: $18,057
Gastroenterology $18,057
Dr. Steven Harrell, M.d, M.D
Gastroenterology — Payments: $14,382
Gastroenterology $14,382
Dr. Abdul Jabbar, Md, MD
Gastroenterology — Payments: $11,309
Gastroenterology $11,309
Dr. Emori Carrara, M.d, M.D
Gastroenterology — Payments: $4,485
Gastroenterology $4,485